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S U M M A R Y
Background: Clinical reasoning utilizing certain symptoms and scores has not proven to be a reliable
decision-making tool to determine whether or not to suspect a group A Streptococcus (GAS) infection in
the patient presenting with a sore throat. Culture as the so-called ‘gold standard’ is impracticable
because it takes 1 to 2 days (and even longer in remote locations) for a result, and thus treatment
decisions will be made without the result available. Rapid diagnostic antigen tests have demonstrated
sufficient sensitivities and specificities in detecting GAS antigens to identify GAS throat infections.
Methods: Throat swab samples were collected from patients attending the Mount Isa Hospital
emergency department for a sore throat; these samples were compared to swab samples collected from
healthy controls who did not have a sore throat. Both groups were aged 3–15 years. All swab samples
were analyzed with a point-of-care test (Alere Test Pack +Plus with OBC Strep A). The etiologic predictive
value (EPV) of the throat swab was calculated.
Results: The 95% confidence interval for positive EPV was 88–100% and for negative EPV was 97–99%,
depending on assumptions made.
Conclusion: This study demonstrates that the point-of-care test Alere Test Pack +Plus Strep A has a high
positive predictive value and is able to rule in GAS infection as long as the proportion of carriers is low.
Also the negative predictive value for ruling out GAS as the etiologic agent is very high irrespective of the
carrier rate. Hence, this test is always useful to rule out GAS infection.
 2016 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/4.0/).
Contents lists available at ScienceDirect
International Journal of Infectious Diseases
jou r nal h o mep ag e: w ww .e lsev ier . co m / loc ate / i j id1. Introduction
With an incidence of 3–13 cases per 100 patient-years, Group A
Streptococcus (GAS) pharyngitis is a common presentation, not
only in primary health care but also in emergency departments.1
Amongst all patients presenting with a sore throat, the incidence of* Corresponding author at: Associate Professor Ulrich Orda, Mount Isa Hospital
Emergency Department 30 Camooweal Street, Mount Isa, QLD, 4825, Australia.
E-mail address: ulrich.orda@gmail.com (U. Orda).
http://dx.doi.org/10.1016/j.ijid.2016.02.002
1201-9712/ 2016 The Authors. Published by Elsevier Ltd on behalf of International So
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).GAS infection reported in the literature ranges from almost 0% to
40%.2,3 Both the incidence of acute presentations and the severity
may vary over time, and infections may occur in clusters.4
GAS pharyngitis is a main cause of acute rheumatic fever (ARF)
and rheumatic heart disease.5Whilst the absolute global burden of
GAS disease is not exactly known, estimated annual numbers of
rheumatic heart disease cases worldwide of approximately
2 400 0006 to 12 000 0007 have been reported. North Queensland,
Australia, has one of the highest incidences of ARF and rheumatic
heart disease in the world, especially within the indigenousciety for Infectious Diseases. This is an open access article under the CC BY-NC-ND
Table 1
Etiologic predictive value (EPV) of the testsa
Estimated sensitivity
to find GAS
Estimation
of thetab
Positive
EPV
Negative
EPV
0.97 1.0 98 (88–100)% 99 (98–99)%
0.95 1.0 98 (88–100)% 98 (97–99)%
0.97 1.1 98 (88–100)% 99 (98–99)%
0.95 1.1 98 (88–100)% 98 (97–99)%
GAS, group A Streptococcus.
a The EPV of tests states the probability that the test finding is linked to
symptoms/signs while considering symptomatic carriers ill from another agent
(such as a virus).
b Theta is the estimated prevalence of GAS among symptomatic patients ill from
something other than GAS, usually a virus; 1.0 means the prevalence is the same as
among the healthy individuals and 1.1 means a 10% higher prevalence than in
asymptomatic healthy individuals.
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100 000 population.5,8 This is due to a high percentage of residents
in this region living in remote communities, often in varying
degrees of poverty and crowding, and is consistent with findings in
the Northern Territory, Australia.9
Whilst there is increasing suspicion and some evidence that
ARF may also be related to chronic skin sores (pyoderma),5 patients
having a sore throat remain the main focus.
Identifying the individual patient presenting with a sore throat
as having a GAS infection is more challenging than it seems on first
sight, not even taking into account whether all positive GAS results
actually represent an acute bacterial infection.10 Utilizing clinical
decision rules based solely on symptoms and signs, such as the
Centor criteria and World Health Organization criteria, does not
appear to be reliable enough to clarify whether the infective agent
is GAS or not, and thus whether to treat with antibiotics or not.10,11
The resulting problems are an untreated GAS infection that may
lead to ARF, and more often, the unnecessary prescription of
antibiotics leading to side effects as well as the potential of bacteria
developing antibiotic resistance.
Throat culture has been recommended as an aide for treatment
decisions.1,12 However, it has been shown that the 1–2 days of
delay until the result is available results in the decision being made
without considering the outcome of the culture.13,14 Furthermore,
in the setting in which a large number of patients travel several
hundred kilometers to see a doctor and where there is limited
phone reception, it is difficult to organize re-presentation or
follow-up of the results including treatment modifications.
An excellent solution for this dilemma would be a bedside rapid
antigen detection test (RADT) for GAS that provides a positive or
negative result within 5–10 min, thus directly influencing the
treatment decision. Such RADTs have been evaluated previously
using throat culture as the gold standard and initially showed
insufficient sensitivity and specificity.12,15 Later studies have
provided evidence that the sensitivity of GAS RADT is equal or
superior to culture, and specificity close to 100%.16,17,18
The aim of this study was to evaluate the ability of a RADT to
rule in or out a true link between the symptom of a sore throat and
the test outcome while considering the potential of GAS carriers.
2. Materials and methods
Two groups of participants were recruited consecutively. The
first comprised healthy controls. These were children aged 3–15
years presenting consecutively at the Mount Isa Hospital emergency
department (ED) in northwest Queensland, Australia, for reasons
other than infection, thus ensuring that a positive GAS RADT result in
this group would represent asymptomatic carriage. The second
group comprised patients with a sore throat. These were children
aged 3–15 years presenting consecutively at the Mount Isa Hospital
ED in northwest Queensland, Australia, for a sore throat. None of
these children had previously had rheumatic fever.
Once consent was obtained, a throat swab was collected from
each child. This was done using the Dacron swab provided with the
test kit. The swab was sealed in a specimen bag, together with a
data collection sheet and a signed consent form, put in an envelope,
and stored in a refrigerator at approximately 6 8C outside the
clinical area.
The study team processed the swabs within 72 h using the Alere
Test Pack +Plus with OBC Strep A kit (Alere, Waltham, MA, USA).
This test kit has shown a 95%19 to 97%17 sensitivity (the
manufacturer quotes a 97% sensitivity) and a specificity of 95%17
to 100%19 to detect GAS. In this study the outcomes were compared
with the assumption that the sensitivity of the point-of-care test
was 95% and with the assumption that the sensitivity was 97%. The
treating clinician was blinded to the point-of-care test result.The intention was to collect up to 200 samples in each group,
with an interim analysis after approximately 50% of samples had
been obtained.
2.1. Statistical analysis
The etiologic predictive value (EPV) is a statistical method
developed to link symptoms and signs to test findings, hence
linking potential etiologic agents such as a bacterium, while taking
carriers into consideration.20 To calculate the EPV, it is necessary to
have the proportion of positive tests among patients, the
proportion of positive tests among a healthy control population,
and the sensitivity of the test to find what it is designed to look for.
This enables the positive and negative predictive values, including
95% confidence intervals, to be calculated in a situation where a
gold standard for comparison is not present or is questionable and
the population prevalence of GAS is previously unknown.20 The
influence of different assumptions for theta (the assumed ratio
between the proportion of carriers of GAS among healthy
individuals and those with a sore throat caused by a virus) was
also explored.21
Ethics approval was granted by the Townsville Hospital and
Health Service, Human Research and Ethics Committee (HREC/13/
QTHS/260).
3. Results
From June 30, 2014 to February 27, 2015, 248 throat swabs
were collected and examined within 72 h. Two parents refused
the collection of swabs for the purpose of this study. Out of the
101 patients presenting with a sore throat, 26 (26%) tested
positive for GAS. Only one (0.7%) of the 147 control patients had
a positive test result. Statistical analysis showed both the
positive and negative EPV to be high (Table 1). The confidence
intervals in this interim analysis were deemed to be narrow
enough and hence further data collection was cancelled.
4. Discussion
The main finding of this study was that both the positive and
negative EPV indicated that this RADT can be used to both rule in
and rule out a link between symptoms and GAS for the study
population. However, this conclusion may not be valid in other
circumstances where the prevalence of carriers or the proportion
of patients having GAS is different. The incidence of GAS
colonization of the pharynx in asymptomatic patients reported
in the literature is controversial and ranges from less than 2% to
11%.22 Some authors refer to GAS carriers as sources for recurrent
infections and deem the rate of asymptomatic carriers to be as high
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Figure 1. Variation in the positive etiologic predictive value depending on the
carrier rate and prevalence of GAS among patients, assuming a sensitivity of the test
of 95%, as with a rapid antigen detection test (reproduced with the kind permission
of R. Gunnarsson21).
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Figure 2. Variation in the negative etiologic predictive value depending on the
carrier rate and prevalence of GAS among patients, assuming a sensitivity of the test
of 95%, as with a rapid antigen detection test (reproduced with kind permission of R.
Gunnarsson21).
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Furthermore, the proportion of patients having GAS may vary in
different settings from close to zero up to 40%.2,3 In unselected
cases in primary health care or similar settings it would most often
be between 5% and 25%.
Clinical decision rules have not shown appropriate predictive
values to be considered sufficient for clinical decision-making
alone as to whether or not to treat a sore throat as a GAS
infection.7,10,24 Focusing on patients with severe pharyngitis alone
may increase the positive predictive value of a decision-making
rule, but would focus only on a small subgroup of patients.
Culture has historically been considered the gold standard, not
only for diagnostics in clinical practice, but also for rating other
diagnostic methods.1,24,25 However it has been shown that modern
GAS RADTs have similar or better sensitivity than culture,17,18
especially when assessed using PCR testing, the gold standard in
many other areas of diagnostics of infectious diseases. PCR tests
have shown positive results for patient samples testing positive
with a RADT but negative with culture,26 demonstrating that some
RADTs are more sensitive than culture when assessed against PCR
as the gold standard.26,27
Whilst the benefit of a bedside test for decision-making is
widely acknowledged,14,28 the benefit of older generation tests has
been controversial,14 demonstrating a lower sensitivity for a small
inoculum size.29 However it has been found that even the
utilization of older generations of bedside tests in the ED and
other acute care settings is significantly better than clinical
judgment alone,24,30 especially in combination with history,
examination, and a clinical decision rule.28
The sensitivity/specificity and predictive values of several
RADTs have been deemed sufficient for diagnosis and management
in other studies,1,31 including the test utilized for the present
study, which has shown excellent predictive values.
This study is the first to calculate EPV for a RADT in the setting of
sore throat patients. The influence of different assumptions was
tested, such as the sensitivity of the test and theta. The
assumptions most likely to reflect the reality would be a sensitivity
of RADT to detect the presence of GAS of 95–97% with a theta of 1.21
Thus, the positive EPV would be 98 (88–100)% and subsequent
negative EPV 98–99 (97–99)%. Hence, a negative RADT would rule
out the possibility of a sore throat being caused by GAS with a
probability of 97%.
A strength of this study was the use of an established low-cost
RADT with a high sensitivity and specificity. This test should
normally be performed in the clinic or ED by a doctor (general
practitioner, registrar, or emergency physician) or a nurse,
producing a result within minutes. The tests were analyzed in
batches in this study and the outcomes were not given to the
treating doctor. The reason for this was that the aim of the study
was to establish predictive values of tests rather than the actual
influence that this RADT might have on decision-making.
The direct findings of this study are applicable to unselected
presentations of children aged 3–15 years having a sore throat,
with a low carrier rate of GAS and around 25% of children with a
sore throat having a positive test for GAS. It can be shown that the
positive EPV remains quite high as long as the proportion of
carriers remains very low (Figure 1). The positive EPV for this RADT
becomes unreliable when the carrier rate of GAS increases
(Figure 1). The negative EPV usable to rule out a link between
symptoms and GAS always remains high, irrespective of the carrier
rate of GAS and for any reasonable change in the proportion of
patients with a sore throat having GAS (Figure 2). Therefore when
utilizing the EPV to rate the post test probability of GAS infection,
the result is transferable not only to different regions once the
numbers of true infections and asymptomatic carriers are
established, but also to every age group.The RADTs are a significant step forward in correctly diagnosing
sore throat and greatly help to prevent unnecessary antibiotic
prescription.10 In Australia they are relatively cheap (AUD 4/USD 3/
EUR 2.70) compared to culture (AUD 29/USD 21.70/EUR 19.30).
PCR tests have even better test performance, with sensitivity and
specificity close to 100%, but are more difficult to use and too
expensive to be used for unselected patients with a sore throat
(varying cost depending on the system used). However, this may
change in the future.
In conclusion, it can be shown mathematically that a point-of-
care test like the Alere Test Pack +Plus Strep A is always useful to
rule out a link between symptoms of a sore throat and GAS. Its
ability to rule in a link between symptoms and GAS depends on the
carrier rate of GAS. Having the results within 5–10 min makes it
ideal for guiding treatment decisions in unselected presentations
of patients with a sore throat.
U. Orda et al. / International Journal of Infectious Diseases 45 (2016) 32–35 35Conflict of interest/Funding: None.
References
1. Lean WL, Arnup S, Danchin M, Steer AC. Rapid diagnostic tests for group A
streptococcal pharyngitis: a meta-analysis. Pediatrics 2014;134:771–81.
2. Cohen JF, Chalumeau M, Levy C, Bidet P, Thollot F, Wollner A, et al. Spectrum and
inoculum size effect of a rapid antigen detection test for group A Streptococcus
in children with pharyngitis. PLoS One 2012;7:e39085.
3. McDonald M, Brown A, Edwards T, Hope A, Amu M, Morey F, et al. Apparent
contrasting rates of pharyngitis and pyoderma in regions where rheumatic
heart disease is highly prevalent. Heart Lung Circ 2007;16:254–9.
4. Schwartz B, Elliott JA, Butler JC, Simon PA, Jameson BL, Welch GE, et al. Clusters
of invasive group A streptococcal infections in family, hospital, and nursing
home settings. Clin Infect Dis 1992;15:277–84.
5. RHD Australia (ARF/RHD writing group), National Heart Foundation of Australia
and the Cardiac Society of Australia and New Zealand. Australian guideline for
prevention, diagnosis and management of acute rheumatic fever and rheumatic
heart disease. 2nd ed. Menzies School of Health Research; 2012.
6. Carapetis JR, Steer AC, Mulholland EK, Weber M. The global burden of group A
streptococcal diseases. Lancet Infect Dis 2005;5:685–94.
7. Rimoin AW, Hamza HS, Vince A, Kumar R, Walker CF, Chitale RA, et al. Evalua-
tion of the WHO clinical decision rule for streptococcal pharyngitis. Arch Dis
Child 2005;90:1066–70.
8. Hanna JN, Heazlewood RJ. The epidemiology of acute rheumatic fever in
indigenous people in north Queensland. Aust N Z J Public Health 2005;29:
313–7.
9. Lawrence JG, Carapetis JR, Griffiths K, Edwards K, Condon JR. Acute rheumatic
fever and rheumatic heart disease: incidence and progression in the Northern
Territory of Australia, 1997 to 2010. Circulation 2013;128:492–501.
10. Gunnarsson MS, Sundvall PD, Gunnarsson R. In primary health care, never
prescribe antibiotics to patients suspected of having an uncomplicated sore
throat caused by group A beta-haemolytic streptococci without first confirming
the presence of this bacterium. Scand J Infect Dis 2012;44:915–21.
11. Wessels MR. Clinical practice. Streptococcal pharyngitis. N Engl J Med
2011;364:648–55.
12. Huck W, Reed BD, French T, Mitchell RS. Comparison of the Directigen 1-2–3
Group A Strep Test with culture for detection of group A beta-hemolytic
streptococci. J Clin Microbiol 1989;27:1715–8.
13. Makela M. Effect of latex agglutination test on prescribing for group A strepto-
coccal throat disease in primary care. Scand J Infect Dis 1989;21:161–7.
14. Jonckheer T, Goossens H, De Donder M, Levy J, Butzler JP. Evaluation of the
direct detection of group A beta-hemolytic streptococcal antigen in a pediatric
population: comparison with the traditional culture technique. Eur J Epidemiol
1986;2:205–7.
15. Hoffmann S. Detection of group A streptococcal antigen from throat swabs with
five diagnostic kits in general practice. Diagn Microbiol Infect Dis 1990;13:209–15.16. Yuckienuz SA, Thorne GM, Macone AB, Goldmann DA, St Pierre J, Marcus EP.
Performance of a solid phase enzyme immunoassay for detection of group A
streptococci in a pediatric office laboratory as refereed by a hospital laboratory.
Pediatr Infect Dis J 1988;7:393–8.
17. Lindbaek M, Hoiby EA, Lermark G, Steinsholt IM, Hjortdahl P. Which is the best
method to trace group A streptococci in sore throat patients: culture or GAS
antigen test? Scand J Prim Health Care 2004;22:233–8.
18. Kaplan EL, Top Jr FH, Dudding BA, Wannamaker LW. Diagnosis of streptococcal
pharyngitis: differentiation of active infection from the carrier state in the
symptomatic child. J Infect Dis 1971;123:490–501.
19. Lasseter GM, McNulty CA, Richard Hobbs FD, Mant D, Little P, Investigators P. In
vitro evaluation of five rapid antigen detection tests for group A beta-haemo-
lytic streptococcal sore throat infections. Fam Pract 2009;26:437–44.
20. Gunnarsson RK, Lanke J. The predictive value of microbiologic diagnostic tests if
asymptomatic carriers are present. Stat Med 2002;21:1773–85.
21. Gunnarsson R. Microbiologic diagnostic tests when asymptomatic carriers are
present. Aspects of the use of conventional throat and nasopharyngeal cultures
as examples. Doctoral Thesis. University of Gothenburg, Sweden; 2001. Avail-
able at: http://hdl.handle.net/2077/15233 (accessed 02/10/2012).
22. Carapetis JR, Currie BJ, Kaplan EL. Epidemiology and prevention of group A
streptococcal infections: acute respiratory tract infections, skin infections,
and their sequelae at the close of the twentieth century. Clin Infect Dis
1999;28:205–10.
23. Sepdham D, Rao S, Hitchcock K, Goodwin MA. Clinical inquiries: should you
treat carriers of pharyngeal group A strep? J Fam Pract 2008;57:673–4.
24. Cohen JF, Cohen R, Levy C, Thollot F, Benani M, Bidet P, et al. Selective testing
strategies for diagnosing group A streptococcal infection in children with
pharyngitis: a systematic review and prospective multicentre external valida-
tion study. CMAJ 2015;187:23–32.
25. Rogo T, Schwartz RH, Ascher DP. Comparison of the Inverness Medical Acceava
Strep A test with the Genzyme OSOM and Quidel QuickVue Strep A tests. Clin
Pediatr (Phila) 2010;49:1050–2.
26. Cohen JF, Cohen R, Bidet P, Levy C, Deberdt P, d’Humieres C, et al. Rapid-antigen
detection tests for group A streptococcal pharyngitis: revisiting false-positive
results using polymerase chain reaction testing. J Pediatr 2013;162:1282–4.
27. Uhl JR, Adamson SC, Vetter EA, Schleck CD, Harmsen S, Iverson LK, et al.
Comparison of LightCycler PCR, rapid antigen immunoassay, and culture for
detection of group A streptococci from throat swabs. J Clin Microbiol
2003;41:242–9.
28. Ebell MH, Smith MA, Barry HC, Ives K, Carey M. The rational clinical examina-
tion. Does this patient have strep throat? JAMA 2000;284:2912–8.
29. Gerber MA, Spadaccini LJ, Wright LL, Deutsch L. Latex agglutination tests for
rapid identification of group A streptococci directly from throat swabs. J Pediatr
1984;105:702–5.
30. DuBois D, Ray VG, Nelson B, Peacock JB. Rapid diagnosis of group A strep
pharyngitis in the emergency department. Ann Emerg Med 1986;15:157–9.
31. Corneli HM. Rapid detection and diagnosis of group A streptococcal pharyngitis.
Curr Infect Dis Rep 2004;6:181–6.
